Key result
Severe cardiotoxicity from high-risk anticancer therapy is linked to ~10-fold higher mortality.
Why the study?
Cardiotoxicity is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking.
What is the prevalence and prognostic impact of anticancer therapy-induced cardiotoxicity?
What is the prevalence and prognostic impact of anticancer therapy-induced cardiotoxicity?
While mild cardiotoxicity is common during or after cancer therapy, severe cardiotoxicity is rare but strongly associated with increased mortality.
Answers are grounded in this paper and cite their sources.
Severe cardiotoxicity was associated with high mortality in cancer patients; extends prior observations but leaves causal inference and practice change open.
Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform diagnostic criteria to guide clinical and research practices are lacking. Methods and results We prospectively studied 865 patients, aged 54.7 ± 13.9; 16.3% men, scheduled for anticancer therapy related with moderate/high CTox risk. Four groups of progressive myocardial damage/dysfunction were considered according to current guidelines: normal, normal biomarkers (high-sensitivity troponin T and N-terminal natriuretic pro-peptide), and left ventricular (LV) function; mild, abnormal biomarkers, and/or LV dysfunction (LVD) maintaining an LV ejection fraction (LVEF) ≥50%; moderate, LVD with LVEF 40–49%; and severe, LVD with LVEF ≤40% or symptomatic heart failure. Cardiotoxicity was defined as new or worsening of myocardial damage/ventricular function from baseline during follow-up. Patients were followed for a median of 24 months. Cardiotoxicity was identified in 37.5% patients during follow-up [95% confidence interval (CI) 34.22–40.8%], 31.6% with mild, 2.8% moderate, and 3.1% with severe myocardial damage/dysfunction. The mortality rate in the severe CTox group was 22.9 deaths per 100 patients-year vs. 2.3 deaths per 100 patients-year in the rest of groups, hazard ratio of 10.2 (95% CI 5.5–19.2) (P < 0.001). Conclusions The majority of patients present objective data of myocardial injury/dysfunction during or after cancer therapy. Nevertheless, severe CTox, with a strong prognostic relationship, was comparatively rare. This should be reflected in protocols for clinical and research practices.
No takes yet. Share an insight, caveat, or question.
López‐Sendón et al. (2020) studied this question. Cardiotoxicity was identified in 37.5% of patients, with severe cases exhibiting a mortality rate of 22.9 deaths per 100 patient-years compared to 2.3 in other groups.
Synapse has enriched 10 related papers. Consider them for comparative context: